Annual report pursuant to Section 13 and 15(d)

CONCENTRATIONS

v2.4.1.9
CONCENTRATIONS
12 Months Ended
Dec. 31, 2014
Notes to Financial Statements  
Note 17 - CONCENTRATIONS

Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash, cash equivalents and trade receivables. The Company places its cash and temporary cash investments with high credit quality institutions. At times, such investments may be in excess of the FDIC insurance limit.

 

The Company’s revenues earned from sale of products and services for the year ended December 31, 2014 included 21% and 15% (aggregate of 36%) from two customers of the Company’s total revenues.

 

The Company’s revenues earned from sale of products and services for the year ended December 31, 2013 included an aggregate of 26% from one customer of the Company’s total revenues.

 

Three customers accounted for 65%, 16% and 10% of the Company’s total accounts receivable at December 31, 2014; and one customer accounted for 17% of total accounts receivable at December 31,2013.

 

The Company relies on Trinity Rx as its sole supplier of its Naltrexone implant.